In silico evaluation of the effects of temperature on the affinity of the SV2C ligand UCB-1A to SV2 isoforms

This study combines experimental binding assays and molecular dynamics simulations to demonstrate that the SV2C-selective ligand UCB-1A maintains stable binding at physiological temperatures due to a unique hydrogen bond involving Tyr298, whereas its binding to SV2A is significantly destabilized by heat, providing a mechanistic explanation for the ligand's temperature-independent selectivity.

The Gist

The Big Picture: Finding the Perfect Key for a Lock

Imagine your brain is a bustling city, and the Synaptic Vesicle Glycoproteins (SV2) are the traffic lights and delivery trucks that keep the city running smoothly. There are three slightly different models of these trucks: SV2A, SV2B, and SV2C.

Scientists want to build a special "key" (a drug called UCB-1A) that fits only into the SV2C truck. This is important because SV2C is involved in conditions like epilepsy and Parkinson's disease. If we can target SV2C specifically, we might be able to treat these diseases without messing up the other trucks (SV2A and SV2B).

The Problem: The "Cold vs. Hot" Test

Usually, when scientists test if a key fits a lock, they do it in a cold room (4°C). Why? Because it keeps the proteins stable and stops them from falling apart during the test.

However, there was a previous key (called UCB-F) that looked amazing in the cold room. It fit perfectly! But when they tried to use it in a living body (which is warm, at 37°C), it failed completely. It was like a key that worked in a freezer but wouldn't turn in a warm lock.

The researchers wanted to know: Does the new key, UCB-1A, suffer from the same problem? Does it work in the cold but fall apart in the heat?

The Experiment: A Two-Part Detective Story

To solve this, the team used two methods:

1. The Lab Test: They physically tested the key in the cold (4°C) and the heat (37°C).
2. The Computer Simulation: They built a digital movie of the key and the lock interacting, running it thousands of times to see what happens when the temperature changes.

The Results: One Key, Two Different Reactions

1. The Lab Results:

• SV2A (The "Old" Truck): When the temperature went up, the key slipped out. The bond got weak. It was like trying to hold onto a wet bar of soap in a hot shower; it just wouldn't stay put.
• SV2C (The "New" Truck): When the temperature went up, the key stayed locked in tight. It didn't care about the heat at all.

2. The Computer Movie (The "Why"):
The scientists zoomed in on the digital models to see why this happened. They found that both trucks have a similar shape, but there was one tiny, crucial difference in the SV2C truck.

• The "Velcro" Effect: Inside the SV2C truck, there is a specific part (a molecule called Tyr298) that acts like a piece of Velcro. It has a special "sticky" connection (a hydrogen bond) with a neighbor molecule (Asn) right next to it.
• The "Dry" Pocket: Because of this Velcro connection, the inside of the SV2C pocket stays dry. Water molecules (which usually act like slippery oil) can't get in to wash the key away.
• The SV2A Difference: The SV2A truck lacks this Velcro. Its pocket is wet and slippery. When the temperature rises, the water gets more active, the "slippery oil" increases, and the key slides right out.

The Analogy: The Tent vs. The Umbrella

Imagine you are trying to keep a tent (the drug) attached to a pole (the protein) during a storm (heat).

• SV2A is like a tent with a loose rope. In calm weather (cold), it stays up. But as the wind picks up (heat), the rope slips, and the tent falls down.
• SV2C is like a tent with a heavy-duty stake and a guy-line. Even when the wind picks up, the extra stake (the special hydrogen bond) and the dry ground (lack of water) keep the tent firmly planted. It doesn't budge.

Why This Matters

This study is a huge win for drug design. It teaches us two main lessons:

1. Don't trust the cold room: Just because a drug works in a cold lab doesn't mean it will work in a warm human body. We must test drugs at body temperature (37°C) to be sure.
2. Small details make big differences: A tiny change in the shape of a protein (like having that one extra "Velcro" stake) can make the difference between a drug that fails and a drug that saves lives.

In short: The new drug UCB-1A is a winner. It stays locked onto its target (SV2C) even when the body gets hot, thanks to a special molecular "Velcro" that keeps it from slipping away. This gives scientists hope that they can finally create better treatments for brain disorders.

Technical Summary

1. Problem Statement

Synaptic vesicle glycoproteins (SV2), specifically isoforms SV2A, SV2B, and SV2C, are critical for neurotransmitter release and are targets for treating neurological disorders like epilepsy and Parkinson's disease. A significant challenge in drug discovery for these membrane proteins is the temperature dependence of ligand binding.

• The Issue: Many in vitro binding assays are conducted at low temperatures (e.g., 4 °C) to stabilize proteins, but physiological conditions are 37 °C. Previous studies showed that the ligand UCB-F had high affinity for SV2C at 4 °C but lost ~10-fold affinity at 37 °C, leading to a failure in in vivo PET imaging despite promising in vitro results.
• The Specific Case: A new ligand, UCB-1A, was identified with high selectivity for SV2C. However, unlike UCB-F, UCB-1A exhibited temperature-independent binding to SV2C in experimental assays, while its binding to SV2A remained temperature-sensitive.
• The Knowledge Gap: The molecular mechanism explaining why UCB-1A maintains stable binding to SV2C at physiological temperatures, while losing stability in SV2A, was unknown. Understanding this is crucial for rational drug design and reliable biomarker development.

2. Methodology

The study employed a hybrid approach combining experimental binding data with computational molecular dynamics (MD) simulations.

• Experimental Data:
  • Utilized existing in vitro binding affinity data ($pK_i$) for UCB-1A against human recombinant SV2A and SV2C at both 4 °C (277 K) and 37 °C (310 K).
• Computational Modeling (MD Simulations):
  • Structure Preparation:
    • SV2A: Used the crystal structure of human SV2A with a co-crystallized ligand (PDB ID: 8UO9) as a template. UCB-1A was docked by aligning it with the co-crystallized ligand.
    • SV2C: Generated a homology model based on the relaxed SV2A–UCB-1A structure.
    • System Setup: Complexes were embedded in a POPC lipid bilayer, solvated with TIP3P water, and neutralized with Na⁺/Cl⁻ ions.
  • Simulation Protocol:
    • Force Field: OPLS4 (optimized for protein-ligand interactions in membranes).
    • Conditions: Simulations were run at 277 K (4 °C) and 310 K (37 °C).
    • Sampling: 10 independent replicas (100 ns each) were performed for each isoform at each temperature to ensure statistical robustness.
  • Analysis:
    • Ligand Stability: Root Mean Square Deviation (RMSD) of UCB-1A was calculated to assess binding stability (cutoff: 3.0 Å).
    • Solvation & Interactions: Analyzed water molecule counts near key residues and hydrogen bond persistence between specific amino acids (Tyr298 and Asn) and the ligand.

3. Key Results

A. Experimental Validation

• SV2A: Binding affinity decreased significantly from 4 °C ($pK_i$ = 7.2) to 37 °C ($pK_i$ = 6.1), indicating a ~10-fold loss in affinity.
• SV2C: Binding affinity remained stable and temperature-independent ($pK_i$ = 8.3 at 4 °C vs. 8.4 at 37 °C).

B. Molecular Dynamics Findings

• RMSD Analysis (Stability):
  • At 277 K, UCB-1A remained stably bound in both SV2A and SV2C (all trajectories < 3.0 Å).
  • At 310 K, a divergence occurred:
    • SV2A: 6 out of 10 replicas showed RMSD > 3.0 Å, indicating partial dissociation or unstable binding.
    • SV2C: Only 2 out of 10 replicas exceeded the 3.0 Å cutoff, confirming high thermal stability.
• Conserved Binding Mode: Both isoforms shared a common binding pose stabilized by $\pi$–$\pi$ stacking and a hydrogen bond with an Aspartate (Asp) residue.
• Isoform-Specific Stabilization (The Mechanism):
  • SV2C Specific Feature: In SV2C, the residue Tyr298 is less exposed to solvent (average 1.0 water molecule) compared to SV2A (1.89 water molecules).
  • Hydrogen Bond Network: In SV2C, Tyr298 forms a persistent hydrogen bond with Asparagine (Asn). This interaction was maintained at both 277 K and 310 K (distances ~2.87 Å and ~3.10 Å, respectively).
  • SV2A Deficiency: The corresponding position in SV2A is a Glycine (Gly), which cannot form this stabilizing hydrogen bond network. Consequently, the binding pocket in SV2A is more hydrated and flexible at physiological temperatures, leading to ligand destabilization.

4. Key Contributions

1. Mechanistic Explanation: The study provides the first structural explanation for the temperature independence of UCB-1A binding to SV2C. It identifies a specific Tyr298–Asn hydrogen bond and reduced solvation as the "thermal buffer" that stabilizes the ligand in SV2C but is absent in SV2A.
2. Validation of Hybrid Approach: It demonstrates the power of combining in vitro assays with in silico MD simulations to uncover isoform-specific mechanisms that are not apparent from static crystal structures alone.
3. Methodological Insight: It highlights the critical importance of testing ligand candidates at physiological temperatures (37 °C) rather than just 4 °C to avoid false positives or misinterpretations of selectivity, particularly for membrane proteins.

5. Significance

• Drug Discovery: The findings offer a blueprint for designing next-generation SV2 ligands. By targeting the specific structural features (like the Tyr298–Asn interaction) that confer thermal stability, researchers can develop more reliable biomarkers and therapeutics.
• Biomarker Reliability: UCB-1A's temperature independence makes it a superior candidate for in vivo imaging (e.g., PET scans) compared to previous ligands like UCB-F, which failed in vivo due to temperature sensitivity.
• General Principle: The study underscores that physiological relevance (temperature) must be integrated early in the hit-to-lead optimization process to ensure successful translation from bench to bedside.